Ipsen’s John Chaddock on making neurotoxins a priority for h...

Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs.  Ipsen’s John Chaddock tells u

Ipsen’s UK & Ireland MD on adapting business to COVID-19

Since entering the pharmaceutical industry as a graduate trainee in the late 1990s, Asad Mohsin Ali’s career has taken him across the business from Novartis, MSD and Tesaro, before joining

David Loew swaps Sanofi’s top vaccine job for CEO role at Ip...

Sanofi had no sooner announced the departure of David Loew, its head of vaccines, before he surfaced as the new chief executive of French specialty drugmaker Ipsen, taking over

Engaging with customers in a digital world

As part of our series on customer experience in pharma, in partnership with Indegene, Ipsen’s Paul Murasko explains the many ways digital can enhance the customer journey – so long as t

Ipsen craters as pricey rare disease drug is put on hold aga...

Allergan gets FDA okay for paediatric Botox use